{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:30:41Z","timestamp":1793845841480,"version":"4.6.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014114","name":"GW Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014114","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["14\/23\/17"],"award-info":[{"award-number":["14\/23\/17"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["643051"],"award-info":[{"award-number":["643051"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH102221"],"award-info":[{"award-number":["R01MH102221"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["Horizon"],"award-info":[{"award-number":["Horizon"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2013-2280"],"award-info":[{"award-number":["2013-2280"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2018-02213"],"award-info":[{"award-number":["2018-02213"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["2020"],"award-info":[{"award-number":["2020"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R00DA040727"],"award-info":[{"award-number":["R00DA040727"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NF-SI-0616-10040"],"award-info":[{"award-number":["NF-SI-0616-10040"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.biopsych.2019.04.009","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:00:21Z","timestamp":1555452021000},"page":"335-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":162,"title":["Risks and Benefits of Attention-Deficit\/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases"],"prefix":"10.1016","volume":"86","author":[{"given":"Zheng","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ghirardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick D.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2667-2254","authenticated-orcid":false,"given":"Philip","family":"Asherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2019.04.009_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/jcpp.12381","article-title":"Annual research review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents","volume":"56","author":"Polanczyk","year":"2015","journal-title":"J\u00a0Child Psychol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1037\/abn0000086","article-title":"Predictors of adolescent outcomes among 4\u20136-year-old children with attention-deficit\/hyperactivity disorder","volume":"125","author":"Lahey","year":"2016","journal-title":"J\u00a0Abnorm Psychol"},{"key":"10.1016\/j.biopsych.2019.04.009_bib3","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/jcpp.12371","article-title":"Annual research review: Optimal outcomes of child and adolescent mental illness","volume":"56","author":"Costello","year":"2015","journal-title":"J\u00a0Child Psychol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S2215-0366(17)30167-0","article-title":"ADHD in children and young people: Prevalence, care pathways, and service provision","volume":"5","author":"Sayal","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib5","doi-asserted-by":"crossref","first-page":"e181471","DOI":"10.1001\/jamanetworkopen.2018.1471","article-title":"Twenty-year trends in diagnosed attention-deficit\/hyperactivity disorder among us children and adolescents, 1997-2016","volume":"1","author":"Xu","year":"2018","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.biopsych.2019.04.009_bib6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/ije\/dyt261","article-title":"ADHD prevalence estimates across three decades: An updated systematic review and meta-regression analysis","volume":"43","author":"Polanczyk","year":"2014","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.biopsych.2019.04.009_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12402-014-0142-1","article-title":"Comorbid mental disorders in children and adolescents with attention-deficit\/hyperactivity disorder in a large nationwide study","volume":"7","author":"Jensen","year":"2015","journal-title":"Atten Defic Hyperact Disord"},{"key":"10.1016\/j.biopsych.2019.04.009_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00004583-200102000-00009","article-title":"ADHD comorbidity findings from the MTA study: Comparing comorbid subgroups","volume":"40","author":"Jensen","year":"2001","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib9","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(15)00238-X","article-title":"Attention deficit hyperactivity disorder","volume":"387","author":"Thapar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2019.04.009_bib10","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(14)61684-6","article-title":"Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: A nationwide cohort study","volume":"385","author":"Dalsgaard","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2019.04.009_bib11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaac.2016.07.774","article-title":"Functional adult outcomes 16 years after childhood diagnosis of attention-deficit\/hyperactivity disorder: MTA results","volume":"55","author":"Hechtman","year":"2016","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib13","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/chi.0b013e318054e724","article-title":"Practice parameter for the assessment and treatment of children and adolescents with attention-deficit\/hyperactivity disorder","volume":"46","author":"Pliszka","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1542\/peds.2011-2654","article-title":"ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents","volume":"128","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.biopsych.2019.04.009_bib15","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/chi.0b013e318054e724","article-title":"Practice parameter for the assessment and treatment of children and adolescents with attention-deficit\/hyperactivity disorder","volume":"46","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib16","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.2016.5453","article-title":"Treatment of attention-deficit\/hyperactivity disorder in adolescents: A systematic review","volume":"315","author":"Chan","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2019.04.009_bib17","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2215-0366(18)30293-1","article-title":"Trends in attention-deficit hyperactivity disorder medication use: A retrospective observational study using population-based databases","volume":"5","author":"Raman","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/cap.2017.0077","article-title":"National patterns of commonly prescribed psychotropic medications to young people","volume":"28","author":"Sultan","year":"2018","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.biopsych.2019.04.009_bib19","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1001\/jama.2016.3427","article-title":"Quantifying the benefits and risks of methylphenidate as treatment for childhood attention-deficit\/hyperactivity disorder","volume":"315","author":"Shaw","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2019.04.009_bib20","doi-asserted-by":"crossref","first-page":"h5203","DOI":"10.1136\/bmj.h5203","article-title":"Methylphenidate for attention-deficit\/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials","volume":"351","author":"Storeb\u00f8","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.biopsych.2019.04.009_bib21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMra1614394","article-title":"Evidence for health decision making\u2014beyond randomized, controlled trials","volume":"377","author":"Frieden","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.biopsych.2019.04.009_bib22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.socscimed.2017.12.005","article-title":"Understanding and misunderstanding randomized controlled trials","volume":"210","author":"Deaton","year":"2018","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.biopsych.2019.04.009_bib23","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.4088\/JCP.09m05344pur","article-title":"Representativeness of participants in a clinical trial for attention-deficit\/hyperactivity disorder? Comparison with adults from a large observational study","volume":"71","author":"Surman","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib24","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/jamapediatrics.2018.1642","article-title":"Moving beyond symptom remission to optimize long-term treatment of attention-deficit\/ hyperactivity disorder","volume":"172","author":"Kollins","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.biopsych.2019.04.009_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/HRP.0000000000000122","article-title":"Pharmacological treatment of ADHD in addicted patients: What does the literature tell us?","volume":"25","author":"Carpentier","year":"2017","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000487767","article-title":"International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit\/hyperactivity disorder","volume":"24","author":"Crunelle","year":"2018","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.biopsych.2019.04.009_bib27","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/01.chi.0000235077.32661.61","article-title":"Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD","volume":"45","author":"Greenhill","year":"2006","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib28","doi-asserted-by":"crossref","first-page":"e1584","DOI":"10.1542\/peds.2012-0974","article-title":"Interventions for preschool children at high risk for ADHD: A comparative effectiveness review","volume":"131","author":"Charach","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.biopsych.2019.04.009_bib29","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jama.2018.10136","article-title":"Real-world evidence and real-world data for evaluating drug safety and effectiveness","volume":"320","author":"Corrigan-Curay","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2019.04.009_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00787-013-0386-x","article-title":"An inventory of European data sources for the long-term safety evaluation of methylphenidate","volume":"22","author":"Murray","year":"2013","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamapsychiatry.2017.4704","article-title":"Enthusiasm and skepticism about using national registers to analyze psychotropic drug outcomes","volume":"75","author":"Leucht","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib32","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.biopsych.2016.10.002","article-title":"Can medication effects be determined using national registry data? A cautionary reflection on risk of bias in \u201cbig data\u201d analytics","volume":"80","author":"Sonuga-Barke","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib33","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by indication in clinical research","volume":"316","author":"Kyriacou","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2019.04.009_bib34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/joim.12186","article-title":"Use of self-controlled designs in pharmacoepidemiology","volume":"275","author":"Hallas","year":"2014","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.biopsych.2019.04.009_bib35","doi-asserted-by":"crossref","first-page":"i4515","DOI":"10.1136\/bmj.i4515","article-title":"Self controlled case series methods: An alternative to standard epidemiological study designs","volume":"354","author":"Petersen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.biopsych.2019.04.009_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00787-010-0140-6","article-title":"European guidelines on managing adverse effects of medication for ADHD","volume":"20","author":"Graham","year":"2011","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib37","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.biopsych.2019.04.009_bib38","doi-asserted-by":"crossref","first-page":"e0173762","DOI":"10.1371\/journal.pone.0173762","article-title":"The association between methylphenidate treatment and the risk for fracture among young ADHD patients: A nationwide population-based study in Taiwan","volume":"12","author":"Chen","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.biopsych.2019.04.009_bib39","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S2215-0366(15)00271-0","article-title":"Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: A prospective cohort study","volume":"2","author":"Dalsgaard","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib40","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00198-016-3842-x","article-title":"Impact of attention deficit hyperactivity disorder therapy on fracture risk in children treated in German pediatric practices","volume":"28","author":"Jacob","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.biopsych.2019.04.009_bib41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1542\/peds.2014-1738","article-title":"Methylphenidate and the risk of trauma","volume":"135","author":"Man","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.biopsych.2019.04.009_bib42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1087054707305168","article-title":"Injury among stimulant-treated youth with ADHD","volume":"12","author":"Marcus","year":"2008","journal-title":"J\u00a0Atten Disord"},{"key":"10.1016\/j.biopsych.2019.04.009_bib43","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamapediatrics.2014.3275","article-title":"Injury prevention by medication among children with attention-deficit\/hyperactivity disorder: A case-only study","volume":"169","author":"Mikolajczyk","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.biopsych.2019.04.009_bib44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1136\/injuryprev-2012-040483","article-title":"Stimulant treatment and injury among children with attention deficit hyperactivity disorder: An application of the self-controlled case series study design","volume":"19","author":"Raman","year":"2013","journal-title":"Inj Prev"},{"key":"10.1016\/j.biopsych.2019.04.009_bib45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00787-013-0432-8","article-title":"Association between ADHD drug use and injuries among children and adolescents","volume":"23","author":"van den Ban","year":"2014","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00787-017-1042-7","article-title":"Dosage of methylphenidate and traumatic brain injury in ADHD: A population-based study in Taiwan","volume":"27","author":"Liao","year":"2018","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ridd.2017.04.011","article-title":"The risk of injury in adults with attention-deficit hyperactivity disorder: A nationwide, matched-cohort, population-based study in Taiwan","volume":"65","author":"Chien","year":"2017","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.biopsych.2019.04.009_bib48","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jadohealth.2018.02.012","article-title":"Risk of traumatic brain injury among children, adolescents, and young adults with attention-deficit hyperactivity disorder in Taiwan","volume":"63","author":"Liou","year":"2018","journal-title":"J\u00a0Adolesc Health"},{"key":"10.1016\/j.biopsych.2019.04.009_bib49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamapsychiatry.2013.4174","article-title":"Serious transport accidents in adults with attention-deficit\/hyperactivity disorder and the effect of medication: A population-based study","volume":"71","author":"Chang","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/jamapsychiatry.2017.0659","article-title":"Association between medication use for attention-deficit\/hyperactivity disorder and risk of motor vehicle crashes","volume":"74","author":"Chang","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib51","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jamapsychiatry.2017.1472","article-title":"Association between medication use and performance on higher education entrance tests in individuals with attention-deficit\/hyperactivity disorder","volume":"74","author":"Lu","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib52","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jaac.2011.02.007","article-title":"Stimulant adherence and academic performance in urban youth with attention-deficit\/hyperactivity disorder","volume":"50","author":"Marcus","year":"2011","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib53","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12888-017-1279-1","article-title":"Methylphenidate use and school performance among primary school children: A descriptive study","volume":"17","author":"van der Schans","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib54","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1542\/peds.2011-3493","article-title":"A\u00a0population-based study of stimulant drug treatment of ADHD and academic progress in children","volume":"130","author":"Zoega","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.biopsych.2019.04.009_bib55","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaac.2018.11.014","article-title":"Attention-deficit\/hyperactivity disorder, school performance, and effect of medication","volume":"58","author":"Jangmo","year":"2019","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib56","doi-asserted-by":"crossref","first-page":"e0207905","DOI":"10.1371\/journal.pone.0207905","article-title":"Medical treatment of attention deficit\/hyperactivity disorder (ADHD) and children\u2019s academic performance","volume":"13","author":"Keilow","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2019.04.009_bib57","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1203241","article-title":"Medication for attention deficit-hyperactivity disorder and criminality","volume":"367","author":"Lichtenstein","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.biopsych.2019.04.009_bib58","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaac.2018.11.016","article-title":"Attention-deficit\/hyperactivity disorder in childhood and adolescence and the risk of crime in young adulthood in a Danish Nationwide Study","volume":"58","author":"Mohr-Jensen","year":"2019","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib59","doi-asserted-by":"crossref","first-page":"g3769","DOI":"10.1136\/bmj.g3769","article-title":"Drug treatment for attention-deficit\/hyperactivity disorder and suicidal behaviour: Register based study","volume":"348","author":"Chen","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.biopsych.2019.04.009_bib60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1192\/bjp.2018.8","article-title":"Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: A nationwide longitudinal study","volume":"212","author":"Huang","year":"2018","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib61","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ridd.2017.10.023","article-title":"Suicide risk reduction in youths with attention-deficit\/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study","volume":"72","author":"Liang","year":"2018","journal-title":"Res Dev Disabil"},{"issue":"5","key":"10.1016\/j.biopsych.2019.04.009_bib62","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3199","article-title":"Risk of suicidal events with atomoxetine compared to stimulant treatment: A cohort study","volume":"137","author":"Linden","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.biopsych.2019.04.009_bib63","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamapsychiatry.2017.2183","article-title":"Association of risk of suicide attempts with methylphenidate treatment","volume":"74","author":"Man","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib64","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/jcpp.12164","article-title":"Stimulant ADHD medication and risk for substance abuse","volume":"55","author":"Chang","year":"2014","journal-title":"J\u00a0child Psychol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib65","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.euroneuro.2013.11.003","article-title":"Substance use disorders in association with attention-deficit\/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample","volume":"24","author":"Steinhausen","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2019.04.009_bib66","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1176\/appi.ajp.2017.16060686","article-title":"ADHD medication and substance-related problems","volume":"174","author":"Quinn","year":"2017","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib67","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.biopsych.2016.02.018","article-title":"Medication for attention-deficit\/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study","volume":"80","author":"Chang","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib68","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jad.2015.09.015","article-title":"Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: A nationwide population-based study in Taiwan","volume":"189","author":"Lee","year":"2016","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.biopsych.2019.04.009_bib69","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1176\/appi.ajp.2016.16040467","article-title":"The risk of treatment-emergent mania with methylphenidate in bipolar disorder","volume":"174","author":"Viktorin","year":"2017","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib70","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jpsychires.2015.10.014","article-title":"Attention-deficit hyperactivity disorder, its pharmacotherapy, and the risk of developing bipolar disorder: A nationwide population-based study in Taiwan","volume":"72","author":"Wang","year":"2016","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.biopsych.2019.04.009_bib71","doi-asserted-by":"crossref","first-page":"e956","DOI":"10.1038\/tp.2016.216","article-title":"Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system","volume":"6","author":"Man","year":"2016","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib72","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.schres.2015.08.033","article-title":"Attention-deficit\/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan","volume":"168","author":"Shyu","year":"2015","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2019.04.009_bib73","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/cap.2017.0110","article-title":"Stimulants do not increase the risk of seizure-related hospitalizations in children with epilepsy","volume":"28","author":"Liu","year":"2018","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.biopsych.2019.04.009_bib74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/157488608784529233","article-title":"The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database","volume":"3","author":"McAfee","year":"2008","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.biopsych.2019.04.009_bib75","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/pds.3390","article-title":"A\u00a0cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications","volume":"22","author":"McAfee","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.biopsych.2019.04.009_bib76","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1212\/WNL.0000000000005213","article-title":"Attention-deficit\/hyperactivity disorder medication and seizures","volume":"90","author":"Wiggs","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2019.04.009_bib77","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/epi.14640","article-title":"Medication treatment for attention-deficit\/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy","volume":"60","author":"Brikell","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopsych.2019.04.009_bib78","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40263-017-0485-1","article-title":"Effectiveness of pharmacological treatment for attention-deficit\/hyperactivity disorder on physical injuries: a systematic review and meta-analysis of observational studies","volume":"31","author":"Man","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopsych.2019.04.009_bib79","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neubiorev.2017.11.007","article-title":"Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: A systematic review and meta-analysis","volume":"84","author":"Ruiz-Goikoetxea","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.biopsych.2019.04.009_bib80","doi-asserted-by":"crossref","first-page":"j4587","DOI":"10.1136\/bmj.j4587","article-title":"Handling time varying confounding in observational research","volume":"359","author":"Mansournia","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.biopsych.2019.04.009_bib81","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/EDE.0000000000000504","article-title":"Brief report: Negative controls to detect selection bias and measurement bias in epidemiologic studies","volume":"27","author":"Arnold","year":"2016","journal-title":"Epidemiology"},{"key":"10.1016\/j.biopsych.2019.04.009_bib82","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jclinepi.2003.12.008","article-title":"Time-dependent bias was common in survival analyses published in leading clinical journals","volume":"57","author":"van Walraven","year":"2004","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.biopsych.2019.04.009_bib83","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pds.4403","article-title":"Primary non-adherence and the new-user design","volume":"27","author":"Li","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.biopsych.2019.04.009_bib84","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.biopsych.2019.04.009_bib85","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/CHI.0b013e31819c23d0","article-title":"The MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study","volume":"48","author":"Molina","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib86","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/jcpp.12684","article-title":"Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit\/hyperactivity disorder: Symptom persistence, source discrepancy, and height suppression","volume":"58","author":"Swanson","year":"2017","journal-title":"J\u00a0Child Psychol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib87","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1002\/sim.3701","article-title":"Flexible modeling of the cumulative effects of time-dependent exposures on the hazard","volume":"28","author":"Sylvestre","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.biopsych.2019.04.009_bib88","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pbb.2016.03.009","article-title":"Necessity for research directed at stimulant type and treatment-onset age to access the impact of medication on drug abuse vulnerability in teenagers with ADHD","volume":"145","author":"Kantak","year":"2016","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2019.04.009_bib89","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamapsychiatry.2013.1273","article-title":"Stimulant medication and substance use outcomes: A meta-analysis","volume":"70","author":"Humphreys","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib90","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaac.2012.12.014","article-title":"Adolescent substance use in the multimodal treatment study of attention-deficit\/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication","volume":"52","author":"Molina","year":"2013","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib91","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1586\/ecp.12.75","article-title":"Under-representation of older adults in pharmacokinetic and pharmacodynamic studies: A solvable problem?","volume":"6","author":"Mangoni","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.biopsych.2019.04.009_bib92","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/17425255.2015.1004310","article-title":"Alterations in drug disposition in older adults","volume":"11","author":"Reeve","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.biopsych.2019.04.009_bib93","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/psyg.12057","article-title":"Risk-benefit analysis of antidepressant drug treatment in the elderly","volume":"14","author":"Alamo","year":"2014","journal-title":"Psychogeriatrics"},{"key":"10.1016\/j.biopsych.2019.04.009_bib94","first-page":"Cd011144","article-title":"Methylphenidate for children and adolescents with autism spectrum disorder","volume":"11","author":"Sturman","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.biopsych.2019.04.009_bib95","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/NDT.S59271","article-title":"Optimal management of ADHD in older adults","volume":"12","author":"Torgersen","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.biopsych.2019.04.009_bib96","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1056\/NEJMoa1110212","article-title":"ADHD drugs and serious cardiovascular events in children and young adults","volume":"365","author":"Cooper","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.biopsych.2019.04.009_bib97","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.2011.1830","article-title":"ADHD medications and risk of serious cardiovascular events in young and middle-aged adults","volume":"306","author":"Habel","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2019.04.009_bib98","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40263-017-0410-7","article-title":"Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: A systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine","volume":"31","author":"Hennissen","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopsych.2019.04.009_bib99","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/1740774513499651","article-title":"Integrating biomarker information within trials to evaluate treatment mechanisms and efficacy for personalised medicine","volume":"10","author":"Dunn","year":"2013","journal-title":"Clin Trials"},{"key":"10.1016\/j.biopsych.2019.04.009_bib100","doi-asserted-by":"crossref","first-page":"15020","DOI":"10.1038\/nrdp.2015.20","article-title":"Attention-deficit\/hyperactivity disorder","volume":"1","author":"Faraone","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.biopsych.2019.04.009_bib101","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/mp.2010.8","article-title":"Endophenotype: A conceptual analysis","volume":"15","author":"Kendler","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib102","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.2018.17091048","article-title":"Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the United States","volume":"175","author":"Compton","year":"2018","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2019.04.009_bib103","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/chi.0b013e31815a56f1","article-title":"Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature","volume":"47","author":"Wilens","year":"2008","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322319312740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322319312740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:03:34Z","timestamp":1777413814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322319312740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":103,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0006322319312740"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2019.04.009","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risks and Benefits of Attention-Deficit\/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2019.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}